Effect of Toll-Like Receptor 3 Agonists on the Functionality and Metastatic Properties of Breast Cancer Cell Model

被引:0
|
作者
Alizadeh, Nastaran [1 ]
Amiri, Mohammad Mehdi [2 ]
Moghadam, Alireza Salek [1 ]
Zarnani, Amir Hassan [1 ]
Saadat, Farshid [3 ]
Safavifar, Farnaz [4 ]
Berahmeh, Azar [4 ]
Khorramizadeh, Mohammad Reza [4 ,5 ,6 ]
机构
[1] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Pathobiol, Tehran, Iran
[3] Guilan Univ Med Sci, Sch Med, Dept Immunol, Rasht, Iran
[4] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Res Inst, Tehran, Iran
[5] Univ Tehran Med Sci, Biosensor Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran
[6] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran
关键词
MDA-MB-231; MMP-2; Poly (A:U); TLR3; APOPTOSIS; TLR3; PROLIFERATION; EXPRESSION; INDUCTION; RESPONSES; PROMOTES; ADJUVANT;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
There exists compelling evidence that Toll-like receptor 3 (TLR3) agonists can directly affect human cancer cells. The aim of this study was to investigate anti-cancer effects of TLR3 agonist in human breast cell line. We assessed potential effects of poly (A:U) on human breast cell line (MDA-MB-231) on a dose-response and time-course basis. Human breast cell line MDA-MB-231 was treated with different concentrations of poly (A:U) and lipopolysaccharide (LPS). Then, the following assays were performed on the treated cells:dose-response and time-course cytotoxicity using colorimetric method; matrix metalloproteinase-2 (MMP-2) activity using gelatin zymography method; apoptosis using annexin-v flowcytometry method; and relative expression of TLR3 and MMP-2 mRNA using reverse transcriptase polymerase chain reaction (RT-PCR) method. Following treatments, dose-response and time-course cytotoxicity using a colorimetric method, (MMP-2) activity (using gelatin zymography), apoptosis (using annexin-v flowcytometry method) assays and expression of TLR3 and MMP-2 genes (using PCR method) were performed. Cytotoxicity and flowcytometry analysis of poly (A:U) showed that poly (A:U) do not have any cytotoxic and apoptotic effects in different concentrations used. MMP-2 activity analysis showed significant decrease in higher concentrations (50 and 100 mu g/ml) between treated and untreated cells. Moreover, poly A:U treated cells demonstrated decreased expression of MMP-2 gene in higher concentrations. Collectively, our data indicated that human breast cancer cell line (MDA-MB-231) was highly responsive to poly (A:U). The antimetastatic effect of direct poly (A:U) and TLR3 interactions in MDA-MB-231 cells could provide new approaches in malignant tumor therapeutic strategy.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 50 条
  • [21] Toll-like receptor 7 agonists and skin
    Novak, Natalija
    Yu, Chun-Feng
    Bieber, Thomas
    Allam, Jean-Pierre
    DRUG NEWS & PERSPECTIVES, 2008, 21 (03) : 158 - 165
  • [22] Toll-Like Receptor Agonists Are They Good Adjuvants?
    Gnjatic, Sacha
    Sawhney, Nikhil B.
    Bhardwaj, Nina
    CANCER JOURNAL, 2010, 16 (04): : 382 - 391
  • [23] Clinical investigations of Toll-like receptor agonists
    Meyer, Thomas
    Stockfleth, Eggert
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1051 - 1065
  • [24] Antiviral applications of Toll-like receptor agonists
    Horscroft, Nigel J.
    Pryde, David C.
    Bright, Helen
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (04) : 789 - 801
  • [25] Toll-like receptor agonists in oncological indications
    Aranda, Fernando
    Vacchelli, Erika
    Obrist, Florine
    Eggermont, Alexander
    Galon, Jerome
    Sautes-Fridman, Catherine
    Cremer, Isabelle
    ter Meulen, Jan Henrik
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2014, 3 (06):
  • [26] Trial Watch Experimental Toll-like receptor agonists for cancer therapy
    Galluzzi, Lorenzo
    Vacchelli, Erika
    Eggermont, Alexander
    Fridman, Wolf Herve
    Galon, Jerome
    Sautes-Fridman, Catherine
    Tartour, Eric
    Zitvogel, Laurence
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2012, 1 (05): : 699 - 716
  • [27] Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
    Iribarren, Kristina
    Bloy, Norma
    Buque, Aitziber
    Cremer, Isabelle
    Eggermont, Alexander
    Fridman, Wolf Herve
    Fucikova, Jitka
    Galon, Jerome
    Spisek, Radek
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2016, 5 (03):
  • [28] Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
    Li, Wei
    Wan, Li
    Duan, Shaojun
    Xu, Jingjing
    MEDICINE, 2022, 101 (01) : E28520
  • [29] Expression and functionality of Toll-like receptor3 in the megakaryocytic lineage
    D'Atri, L. P.
    Etulain, J.
    Rivadeneyra, L.
    Lapponi, M. J.
    Centurion, M.
    Cheng, K.
    Yin, H.
    Schattner, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 839 - 850
  • [30] Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface
    Bondhopadhyay, Banashree
    Moirangthem, Anuradha
    Basu, Anupam
    TUMOR BIOLOGY, 2015, 36 (02) : 1261 - 1271